Trending...
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- Michigan: Attorney General Nessel: Commission's Open Carry Ban at Capitol is 'Not Enough'
- Michigan: Gov. Whitmer, AG Nessel, State Officials Commend Bar and Restaurant Owners for Compliance with COVID-19 Emergency Health Orders
ANN ARBOR, Mich., Jan. 13, 2021 /PRNewswire/ -- EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization. In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies. Amgen is a world leader in the treatment of autoimmune disorders, with a portfolio that includes both innovative medicines, including Otezla® and Enbrel®, and biosimilar products, such as AMGEVITA® (a biosimilar to Humira®) and AVSOLA® (a biosimilar to Remicade®).
More on Michimich.com
About EVOQ Therapeutics
EVOQ Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens for recognition by the immune system. www.evoqtherapeutics.com
SOURCE EVOQ Therapeutics
Related Links
https://www.evoqtherapeutics.com
More on Michimich.com
- Fighting Pest Problems with The Safest Pest Control Dubai Residents Can Get
- Best Advertising Methods To Attract People To Your Events Post COVID-19 by Duluth Businessman Ismail Sirdah
- Thirteen MBK Senior Living Communities Receive "2021 Best of Senior Living" Distinction
- Grassroots Advocacy Group Urges Biden Administration to Appoint a Doctoral Level Mental Health Professional to Lead SAMHSA
- Michigan: Virtual public meeting Jan. 27 for M-3 (Gratiot Avenue) project in Macomb County
About EVOQ Therapeutics
EVOQ Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens for recognition by the immune system. www.evoqtherapeutics.com
SOURCE EVOQ Therapeutics
Related Links
https://www.evoqtherapeutics.com
Filed Under: Business
0 Comments
Latest on Michimich.com
- Michigan: DNR seeks to fill vacancies on UP Citizens' Advisory Councils
- AUA College of Medicine Establishes Admissions Agreement with Mississippi Valley State University
- GameAbove Adds Five Leaders to Advisory Board
- Dollyhood Records Signs Distribution Deal With Sony!
- City of Sterling Heights Partners with Forgotten Harvest to provide Mobile Food Pantry for residents
- J.D. Power Launches Career Development Certification to Identify Companies with Superior Employee Development Initiatives
- West Coast Recording Artist, Composer and Actor, Blue Ragg$ Releases New Music & Theatrical Video
- Swaggerty's Receives Highest Possible Grade from BRC Food Safety Auditors for 8th Consecutive Year
- Be an Example, Get the Covid Shot
- Jurllyshe Announce The Latest Money-saving Strategies of Clothing and Human Hair
- Ziebart Names Jason Case New Corporate Controller While Gearing Up for Strategic Growth
- Sterling Heights: Mid-January Service Update
- Former CEO & Founder of Five Star Custom Foods, Acquired by Cargill, Joins CEO Coaching International
- Thiel College names Terry Eddy to Board of Trustees
- Desktop Metal to Acquire EnvisionTEC, Entering Market for Volume Production Polymer Additive Manufacturing
- Michael Passer Honored With Acclaimed Invitation
- UV Angel Partners with McDonald's Locations in Dallas, Houston, and Chicago and Installs Next Generation Pathogen Control Technology
- "Diamond Fuji" to be Seen from TOKYO SKYTREE in February
- Sterling Heights: January Service Update
- Income Property Organization shares year end report